Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
Updates
View organization page for GenFlow Biosciences
GenFlow Biosciences
1,339 followers
22m
The XPrize Foundation, known for fueling innovative research, has announced a $101 million prize for advancements in anti-aging therapies. The aim is to develop treatments that can significantly reverse aging effects in individuals aged 65-80, focusing on improving muscle, cognition, and immune function. This initiative, the largest in XPrize history, is a testament to the growing importance and potential of longevity research.
At GenFlow Biosciences (LSE: GENF)(OTCQB: GENFF) we believe that aging deserves as much attention as any other global health issue. Our approach, which employs advanced gene delivery techniques, is in the vanguard of addressing the challenges and opportunities of an aging population.
Read more here: hTtps://loom.ly/5zPTJM4
#XPrize #longevity #healthspan #genetherapy
The live feed for the summit has been down all day and so no idea what's been happening, but Eric Verdin CEO of the Buck Institute who sits on Genflow’s Scientific Advisory Board has received $21m in funding. Gl :-)
Updated: 30 November ,2023: 01:32 PM GST
Saudi Arabia’s billion-dollar-a-year anti-aging initiative, the Hevolution Foundation, has announced scientific research grants worth $40 million to fuel transformative breakthroughs in aging science on the closing day of the inaugural Global Healthspan Summit.
Major funding announcements on Thursday included initial pledges $40 million which include $21 million for a novel multi-year partnership with the Buck Institute for Research on Aging to accelerate discoveries toward therapeutic interventions specifically targeting aging.
Cheers Northeast, exciting time to be invested, and this is in addition to Hevolution's planned investments and strategic partnerships which are expected to be announced tomorrow. Gl :-)
XPRIZE on aging will award up to $101 million for therapies that restore vigor to the elderly
Backed by Lulemon’s creator and a Saudi foundation, competition aims to find treatments to extend “health span”
29 NOV 2023
The XPRIZE Foundation today announced $101 million in prizes for researchers who can restore the function of an elderly person’s muscle, cognition, and immune system to a more youthful state.
The competition, backed by Saudi money and the success of a women’s athletic clothing line, seeks drugs, other therapies, and lifestyle strategies that target the biology of human aging to extend a person’s “health span,” or the period of life free of disease or disability. Such breakthroughs could also help prevent chronic diseases closely linked to aging that threaten to overwhelm the health care system. “This is the decade where we’ll see a health span revolution,” says Peter Diamandis, XPRIZE’s founder and executive chair.
htTps://www.xprize.org/prizes/healthspan
Hevolution Global Healthspan Summit...live stream
htTps://m.youtube.com/watch?v=0KT9v_NFfak
Ps Dr Khan was CEO at Life Biosciences, which was founded by the one and only David Sinclair, and so will obviously be very well aware of the potential potency of Sirt6 in longevity, healthspan and multiple disease targets. Gl ;-)
hTtps://www.lifebiosciences.com/dr-mehmood-khan-named-ceo-of-life-biosciences/
Every chance Genflow could be in the frame for significant investment from Hevolution, which would see the sp multi-bag on confirmation. They plan to invest $1 Billion a year to transform R & D into the Longevity space, Major announcements on science, capital investments and strategic partnerships will be made this coming week at Hevolution's Global Healthspan Summit 29-30 November, 2023 Gla :-)
hTtps://youtu.be/_bZCJKV8lRw?si=0QZgDT1sb1ebl19k
Another brilliant and exciting interview with Dr Khan , CEO of Hevolution with Longevity Technology who are invested in Genflow.
Dr Khan confirms there will be major announcements at next week's summit on science, capital and investments, with research institutions and scientists around the world with focus on strategic partnerships and research grants and funding with Academic research institutions and investments into Biotech companies involved with taking the science from Academi research institutions and progressing the R&D towards market....which is exactly what Genflow are doing!!! Gla holders...Excitement building. :-)
Our vision statement is clear: Expand healthy lifespan for the benefit of all’
hTtps://longevity.technology/news/our-vision-statement-is-clear-expand-healthy-lifespan-for-the-benefit-of-all/amp/
"unveil significant investments"
Igniting a New Era in Global Health: Hevolution Foundation Announces Its Inaugural Global Healthspan Summit to Accelerate Scientific Progress for a Rapidly Aging World
NEWS PROVIDED BY
Hevolution Foundation
14 Nov, 2023, 06:24 ET
The largest convening of its kind in Riyadh on Nov. 29 and 30, 2023, the Global Healthspan Summit will catalyze global collaboration around extending healthy years of life, known as "healthspan," and unveil significant investments in the sector.Over 100 international speakers from the US, UK, Egypt, Germany, the Netherlands, Switzerland, Singapore, Spain, and Saudi Arabia and 1000 delegates to convene in Riyadh.With the global population over 60 expected to double to 2 billion by 2050, increasing healthy human healthspan is one of the most urgent issues of our time and could generate savings of $40 trillion per year.With an annual budget of up to $1 billion, Hevolution Foundation is investing in grants for aging research and pioneering impact investments in early-stage biotech.
htTps://www.prnewswire.com/news-releases/igniting-a-new-era-in-global-health-hevolution-foundation-announces-its-inaugural-global-healthspan-summit-to-accelerate-scientific-progress-for-a-rapidly-aging-world-301987392.html
He's also one of the speakers at Hevolution's Global Healthspan Summit end of this month.
htTps://hevolution.com/en/web/guest/ghs-speakers
Eric Verdin is on Genflow’s Scientific Advisory Board.
hTtps://loom.ly/HqJZHZs?trk=organization_guest_main-feed-card-text
‘The longevity revolution has the potential to transform healthcare in our lifetime’
1 HOUR AGO
The Buck Institute’s CEO Eric Verdin on why longevity research has transformative power, but the field must tread carefully between the hype and the noise.
htTps://longevity.technology/news/the-longevity-revolution-has-the-potential-to-transform-healthcare-in-our-lifetime/amp/
I wonder if Jim Mellon's Juvenscene is one of the UK investors Eric has been seeing this week, their Executive Chairman has recently made reference to David Sinclair ( much of his R&D is focused on Sirt6 ) and they've been making and planing more investments in the Longevity space....here's hoping Genflow are one of the companies "really doing compelling things right now"....Excitement building on news from Eric on the series of meetings he's had this week with UK investors. Gla :-)
‘We’re at the longevity inflection point – and the explosion is coming.’
Dr Greg Bailey, the Executive Chairman of Juvenescence
To me, being able to invest right now into antiaging and modifying longevity, is exactly at the inflection point that being given the opportunity to invest in generated AI was at three or four years ago – I think it’s gonna have that sort of explosion. We’re seeing it with some of David Sinclair’s work, we’re going to see some astonishing things out of Altos and BioAge. There’s a number of companies that are doing really compelling things right now that are going to explode the space. And I’m not comparing us with the end game – I think generated AI has enormous societal changes and economics associated with it, but just as far as the trajectory of the curve for next two or three years, this, to me, is the time to invest.
hTtps://longevity.technology/news/were-at-the-longevity-inflection-point-and-the-
A Merry Christmas indeed Porter and what could be a Very Prosperous New Year, as Genflow could be the Star share of 2024 as Eric delivers on expectations and takes Genflow into the spotlight and full investor focus.....Exciting times ahead!!! Gl ;-)
Lots of potential news in the pipeline line to add significant UPside, expected soon, and should be very interesting to see if Eric has anything to report next week on the series of meetings he's had this week with potential UK investors. The appointment of the Joint Broker last week speaks volumes, hopefully very much needed as the demand for shares goes into overdrive!!! Gla :-)
hTtps://loom.ly/MeQymHs
Excitement building...Gla holders...On and most definitely UP!!! :-)
A pre-clinical stage Biotech landed $138m for their antibody AAV delivery system, Genflow’s AAV delivery system is focused on the Sirt6 Gene which is thought to be the most important, potent and compelling gene/protein involved in longevity, healthspan and multiple disease targets....Watch this space...Gla holders...On and UP!!!:-)
VectorY lands $138m to target neurodegeneration with vectorized antibodies
12 HOURS AGO
Dutch biotech VectorY Therapeutics has secured $138 million in a Series A financing round to advance its vectorized antibody programs targeting neurodegenerative diseases. The company’s platform combines precise therapeutic antibodies with one-time AAV-based delivery to the central nervous system.
htTps://longevity.technology/news/vectory-lands-138m-to-target-neurodegeneration-with-vectorized-antibodies/amp/